Daiichi Sankyo Company, Limited (DSNKY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Hiroyuki Okuzawa.
DSNKY hat IPO-Datum 2008-12-12, 18,726 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $32.28B.
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, engaged in the research, development, manufacturing, and marketing of a diverse portfolio of prescription and over-the-counter medicines. The company's key therapeutic areas include oncology, cardiology, diabetes, neurology, and infectious diseases, with notable products such as trastuzumab deruxtecan for cancer treatment, edoxaban for anticoagulation, and teneligliptin for diabetes management. Beyond pharmaceuticals, Daiichi Sankyo also operates in vaccines, animal health, cosmetics, medical devices, and active pharmaceutical ingredients. Founded in 1899, the company leverages strategic collaborations, including partnerships with diagnostic companies, to expand its competitive position in precision medicine and advanced therapies across major global markets.
